Pervasive Developmental Disorder NOS Completed Phase 2 Trials for Aripiprazole (DB01238)

Also known as: Pervasive Developmental Disorder / Pervasive Developmental Disorders / Autistic continuum / Pervasive Development Disorders / Atypical autism / Autism spectrum disorder

IndicationStatusPhase
DBCOND0046531 (Pervasive Developmental Disorder NOS)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00198055A Study of Aripiprazole in Children and Adolescents With Aspergers and Pervasive Developmental Disorder.Treatment
NCT00308074An Open-Label Trial of Aripiprazole in Autism Spectrum DisordersTreatment